

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014635 A2

(51) International Patent Classification?: **C07K 14/47**,
A61K 38/47, C12N 15/56, C12Q 1/34, G01N 33/573

(21) International Application Number:
PCT/EP2004/007842

(22) International Filing Date: 15 July 2004 (15.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/487,351 15 July 2003 (15.07.2003) US
60/487,290 15 July 2003 (15.07.2003) US
60/487,288 15 July 2003 (15.07.2003) US
60/487,391 15 July 2003 (15.07.2003) US

(71) Applicant (for all designated States except US): **GENOVA LTD.**; Canon's Court, 22 Victoria Street, Hamilton HM 12 (**).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGOUD-PUY**, Gullaine [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **BEDERR**, Nassima [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **BOUGUELERET**, Lydie [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **CUSIN**, Isabelle [FR/CH]; c/o GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **MAHE**, Eve [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **NIKNEJAD**, Anne [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine,

CH-1217 Meyrin (CH). **REFFAS**, Samia [CH/CH]; c/o GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **ROSE**, Keith [GB/CH]; c/o GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin (CH). **SAUDRAIS**, Cedric [FR/CH]; c/o GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SECRETED POLYPEPTIDE SPECIES REDUCED IN CARDIOVASCULAR DISORDERS**

(57) Abstract: The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.



WO 2005/014635 A2

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014635 A3

(51) International Patent Classification⁷: **C07K 14/47**,
A61K 38/47, C12N 15/56, C12Q 1/34, G01N 33/573

(CII). ROSE, Kelth [GB/CII]; c/o GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin (CII). SAUDRAIS, Cedric [FR/CII]; c/o GeneProt, Inc., 2, Pré de la Fontaine, CH-1217 Meyrin (CII).

(21) International Application Number:
PCT/EP2004/007842

(74) Agent: GRUBB, Phillip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 15 July 2004 (15.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/487,351	15 July 2003 (15.07.2003)	US
60/487,290	15 July 2003 (15.07.2003)	US
60/487,288	15 July 2003 (15.07.2003)	US
60/487,391	15 July 2003 (15.07.2003)	US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): GENOVA LTD.; Canon's Court, 22 Victoria Street, Hamilton HM 12 (**).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ARGOUD-PUY, Guillaune [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). BEDERR, Nassima [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). BOUGUELERET, Lydle [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). CUSIN, Isabelle [FR/CH]; c/o GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin (CH). MAHE, Eve [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). NIKNEJAD, Anne [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). REFFAS, Samla [CH/CH]; c/o GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
19 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SECRETED POLYPEPTIDE SPECIES REDUCED IN CARDIOVASCULAR DISORDERS

(57) Abstract: The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.



WO 2005/014635 A3